Nicotinamide Riboside Benefits: What Studies Report

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health decision, supplement or medication. It summarises what published research on nicotinamide riboside (NR) has measured and reported, organised by outcome domain, and it does not recommend any use, dose or regimen.

What "benefits" means in the nicotinamide riboside literature

Nicotinamide riboside is a form of vitamin B3 that cells convert into nicotinamide adenine dinucleotide (NAD+), and review articles describe it as one of several NAD+-boosting strategies alongside nicotinamide mononucleotide, nicotinic acid and NAMPT-targeting approaches (PMID 39693020). A 2024 review of NAD+ metabolism set out why NAD+ declines are of research interest and why targeting the pathway is technically difficult, including tissue-specific handling of precursors (PMID 39026037). Because of that framing, most published NR work measures a biochemical outcome — whether NAD+ or its metabolites rise — rather than a hard clinical endpoint, a distinction a 2023 critical review in Science Advances emphasised when it examined what is actually known about NR in humans (PMID 37478182).

Overview of outcome domains studied

NAD+ levels and oral availability: the most replicated finding

The clearest and most frequently cited human result concerns absorption rather than symptoms. In a 2016 study published in Nature Communications, researchers reported that single oral doses of 100 mg, 300 mg and 1,000 mg of nicotinamide riboside increased the blood NAD+ metabolome in healthy adults in a dose-dependent manner, and that NR was orally bioavailable in both mice and humans (PMID 27721479). A 2023 review of NAD+-boosting compounds in humans similarly concluded that raising circulating NAD+ markers is the most reproducible effect observed across supplementation trials, while downstream physiological outcomes were less consistent (PMID 37068054).

Reviews have repeatedly cautioned that a rise in blood NAD+ is not the same as a rise in NAD+ inside the tissues of interest, and that tissue-level pharmacology remains an open question in NAD+ research (PMID 39026037). A 2024 overview of NAD+-boosting strategies made a related point, describing differences between precursors in how they are taken up and metabolised (PMID 39693020).

Neurological outcomes: Parkinson's disease

The NADPARK study was a randomised, double-blind phase I trial in patients with newly diagnosed Parkinson's disease, in which participants received nicotinamide riboside at 1,000 mg per day for 30 days and researchers measured cerebral NAD+ using magnetic resonance spectroscopy (PMID 35235774). The study reported that cerebral NAD+ increased in a subset of participants, that those "NR responders" showed altered cerebral metabolism, and that NR was well tolerated over the 30-day period (PMID 35235774). Because the trial was explicitly phase I and short, its clinical observations were exploratory rather than a demonstration of disease modification, and later clinical overviews listed Parkinson's disease among indications still under investigation for NAD+-targeted approaches (PMID 40926126).

Cognition and mild cognitive impairment

A randomised, placebo-controlled trial published in GeroScience in 2024 tested nicotinamide riboside against placebo in older adults with mild cognitive impairment (PMID 37994989). That design — randomised, placebo-controlled, in a defined clinical population — is the kind of study reviews have called for, but a single trial in one population does not settle whether cognitive endpoints respond, and a 2023 appraisal of human NR data argued that claims about brain and ageing outcomes have generally run ahead of the published evidence (PMID 37478182).

Metabolic, cardiovascular and body-composition endpoints

These are among the most commonly claimed areas and among the least settled. A 2023 review in the Journals of Gerontology surveyed dietary supplementation with NAD+-boosting compounds in humans and described current knowledge as limited, with trials that were typically small and short and with inconsistent findings on metabolic endpoints (PMID 37068054). A 2023 review in Current Nutrition Reports examined nicotinamide mononucleotide and nicotinamide riboside as potential dietary contributors to health and framed their role as a research question rather than an established nutritional benefit (PMID 37273100). The Science Advances review was more pointed, concluding that what is really known about NR supplementation in humans is narrower than marketing-level claims suggest (PMID 37478182).

Muscle and neuromuscular disease biology

A 2025 paper in Skeletal Muscle reported NAD+ dyshomeostasis in RYR1-related myopathies, characterising a disturbance of NAD+ handling in that disease context (PMID 40846977). Work of this type identifies a biological rationale for testing NAD+ precursors; it does not report that nicotinamide riboside improved strength or function in patients. A 2025 overview of clinical NAD+ targeting described a pipeline of indications being explored and stressed that translation from mechanism to clinical benefit has been the central challenge (PMID 40926126).

Kidney injury: related compound, not the same molecule

Searches for NR benefits often surface kidney protection. The published review in that area concerned nicotinamide — a distinct vitamin B3 form — and acute kidney injury, discussing its investigational role rather than reporting established NR outcomes (PMID 34950458). Reviews of NAD+ biology note that different precursors enter the NAD+ pool by different routes, so findings for one compound cannot be assumed to transfer to another (PMID 39693020).

Where the evidence is weak, preclinical or absent

• Lifespan or "anti-ageing" outcomes in humans: no human trial in the verified literature here reported a lifespan outcome; reviews of NAD+-boosting supplementation in humans described the evidence base as early-stage (PMID 37068054).
• Energy, sleep or "cellular repair" claims: the critical 2023 review found that frequently repeated consumer claims about NR were not matched by corresponding human outcome data (PMID 37478182).
• Cancer: a 2023 Nature Communications study reported that niacin restriction combined with NAMPT inhibition was synthetic lethal to neuroendocrine carcinoma in preclinical models, work that concerns NAD+ depletion strategies in tumours rather than supplementation benefit (PMID 38092728). Reviews have flagged that the relationship between NAD+ availability and tumour biology is an active caution in the field (PMID 39026037).
• Dose–response for clinical endpoints: dose-dependency has been reported for blood NAD+ markers (PMID 27721479), not for clinical outcomes, which the 2025 clinical overview listed among unresolved questions (PMID 40926126).

Nicotinamide Riboside Adverse Events: What Studies Report

In the NADPARK trial, researchers reported that nicotinamide riboside at 1,000 mg daily for 30 days was safe and well tolerated in patients with newly diagnosed Parkinson's disease (PMID 35235774). The 2016 human pharmacokinetic study examined single oral doses of 100, 300 and 1,000 mg and reported dose-dependent increases in the NAD+ metabolome without describing a flushing response of the kind associated with nicotinic acid (PMID 27721479). Reviews of human supplementation data have nonetheless noted that trials were generally short, so long-term safety remains incompletely characterised (PMID 37068054), and a 2025 clinical overview listed safety in disease populations among the challenges of targeting NAD+ in the clinic (PMID 40926126).

How to read the evidence base as a whole

Taken together, the published record supports a narrow statement: oral nicotinamide riboside raised blood NAD+ markers in humans in a dose-dependent fashion (PMID 27721479), and trials in defined populations such as Parkinson's disease measured whether that biochemical change reached the brain (PMID 35235774). Beyond that, reviews from 2023 to 2025 converge on describing the clinical evidence as preliminary, with small sample sizes, short durations and heterogeneous endpoints (PMID 37478182, PMID 40926126). Readers comparing sources may find it useful to check, for any claimed benefit, whether the underlying study was human or animal, randomised or observational, and whether the endpoint was a blood marker or a symptom.

Nothing on this page describes a regimen, and no finding here should be read as an outcome that an individual can expect. Regulatory status also differs by jurisdiction and product category, which is a separate matter from what the research literature reports (PMID 37273100).

References

• Nicotinamide riboside is uniquely and orally bioavailable in mice and humans (Nature Communications, 2016)
• Nicotinamide and acute kidney injury (Clinical Kidney Journal, 2021)
• The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease (Cell Metabolism, 2022)
• Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions (The Journals of Gerontology Series A, 2023)
• NAD+ Precursors Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR): Potential Dietary Contribution to Health (Current Nutrition Reports, 2023)
• What is really known about the effects of nicotinamide riboside supplementation in humans (Science Advances, 2023)
• Niacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Nature Communications, 2023)
• A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment (GeroScience, 2024)
• Regulation of and challenges in targeting NAD+ metabolism (Nature Reviews Molecular Cell Biology, 2024)
• NAD(+) Boosting Strategies (Sub-cellular Biochemistry, 2024)
• NAD(+) dyshomeostasis in RYR1-related myopathies (Skeletal Muscle, 2025)
• Emerging strategies, applications and challenges of targeting NAD(+) in the clinic (Nature Aging, 2025)